Rheumatoid Arthritis

The Pharmacy Times® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.
[[thumbnail_alt_text]]
Adalimumab-adaz (Hyrimoz), a biosimilar of Humira, is the third FDA-approved Sandoz biosimilar in the United States.
[[thumbnail_alt_text]]
Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis.
[[thumbnail_alt_text]]
Patients with rheumatoid arthritis who achieve low disease activity or remission may successfully taper their biologic disease-modifying antirheumatic drugs, saving costs as a result.
[[thumbnail_alt_text]]
Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.
[[thumbnail_alt_text]]
By mapping out the epigenomic landscape of rheumatoid arthritis, scientists hope to gain insight on disease origins as well as new cell signaling pathways.
[[thumbnail_alt_text]]
New report assesses the quality of rheumatic disease care across all 50 states and calls for improvements that address access to affordable care.
[[thumbnail_alt_text]]
Top news of the week from Specialty Pharmacy Times.
[[thumbnail_alt_text]]
New drug could serve as a potential treatment option for patients who have shown an inadequate response to conventional disease-modifying drugs.
[[thumbnail_alt_text]]
The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients.
[[thumbnail_alt_text]]
Childhood exposure to secondhand smoke may heighten the risk of developing rheumatoid arthritis (RA) later in life, even in non-smokers, according to new research.